GSK and SCYNEXIS announce agreement to commercialise and further develop Brexafemme
SCYNEXIS will receive an upfront payment of $90 million with future performance-based milestone payments and tiered royalties
SCYNEXIS will receive an upfront payment of $90 million with future performance-based milestone payments and tiered royalties
The approved product is indicated for the treatment of adult patients with Multiple myeloma, in combination with Dexamethasone
lAIH strives to introduce appropriate interventions for nurturing an AMR innovation ecosystem in the country through cohesive efforts across the innovation pyramid
This order is subject to initial advance payment as per the agreed terms of the contract
The company expects the GMP approval from Saudi Food and Drug Authority (SFDA) to soon pave the way for marketing authorizations from the largest market in the GCC region
Standalone Q3 FY23 revenue stood at Rs. 626.5 crore as against Rs. 594.8 crore, a growth of 5% YoY
Products offered on a not-for-profit basis to the 45 lower-income countries now include the full portfolio for which Pfizer has global rights.
The use of procalcitonin testing for sepsis management is highest in the US
With this QIP placement, the Dhanuka group, which took over the company in 2018, is also meeting its mandatory obligation to dilute 15 percent stake in the company by March 2023
The conference is also expected to pave the way for nations to come out with bold and specific political commitments in the 2024 UN General Assembly High-Level Meeting on AMR
Subscribe To Our Newsletter & Stay Updated